Trial · NCT03889795
Phase IB Metformin, Digoxin, Simvastatin in Solid Tumors
NCT03889795, Phase 1, Active not recruiting, Danae Hamouda, MD
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Phase IB Metformin, Digoxin, Simvastatin in Solid Tumors. Trials, record NCT03889795. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT03889795
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Phase IB Metformin, Digoxin, Simvastatin in Solid Tumors
- NCT number
- NCT03889795
- Status
- Active not recruiting
- Phases
- Phase 1
- Enrollment
- 15 participants, estimated
- Lead sponsor
- Danae Hamouda, MD
- Conditions
- Advanced Pancreatic Cancer, Advanced Solid Tumor
- Interventions
- Metformin, Simvastatin, Digoxin
- First posted
- 2019-03-26
- Last updated
- 2025-10-20
Source ClinicalTrials.gov
Registered outcomes5
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Maximum Tolerated Dose and/or Recommended Dose within the tested C3 dose range | Up to one year | Occurrence of any ≥ Grade 3 toxicity encountered within the four weeks following the administration of C3, regardless of attribution |
| Secondary | Safety and Tolerability: Occurrence of treatment - emergent adverse events (TEAEs) and other abnormalities | Up to 2 years | Occurrence of treatment - emergent adverse events (TEAEs) and occurrence of abnormalities in laboratory test values, markedly abnormal vital sign measurements, and clinically significant abnormal electrocardiograms (ECGs), including conduction abnormalities and changes in QT interval |
| Secondary | Efficacy (Disease Response) | Up to 2 years | Response and progression evaluated using Response Evaluation criteria in solid tumors |
| Secondary | Assess BIRC5 levels of expression in tumor tissue | RNA and protein levels of expression at baseline and at 2 months after C3 treatment | Blood samples for pharmacokinetic analysis of C3 will be collected at designated time points. |
| Secondary | Assess molecular changes induced by C3 administration in the blood for biomarker sensitivity/resistance assessment | Baseline and at 2 months | Molecular signal tumor blood (plasma) and microenvironment protein expression patterns via quantitative mass spectrometry. |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT03889795
GET https://conductscience.org/api/trials/v1/NCT03889795/registered